<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02752048</url>
  </required_header>
  <id_info>
    <org_study_id>Taiho10053040</org_study_id>
    <nct_id>NCT02752048</nct_id>
  </id_info>
  <brief_title>A Phase IIa Study of TAS-205 for Duchenne Muscular Dystrophy</brief_title>
  <official_title>A Randomized Phase IIa Study of TAS-205 in Patients With Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiho Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiho Pharmaceutical Co., Ltd.</source>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy after 24-week repeated oral doses of
      TAS-205 in patients with Duchenne Muscular Dystrophy (DMD) in an exploratory manner.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Duchenne Muscular Dystrophy (DMD) is the most common fatal genetic disorder diagnosed in
      childhood, affecting approximately 1 in 3,500 lives male births. DMD patients suffer from a
      relentless decline in muscle strength that impairs the ability of walking and breathing,
      resulting in their lives with wheelchairs and then loss of upper body function. The main
      objective of this study is to evaluate the efficacy after 24-week repeated oral doses of
      TAS-205 in patients with DMD in an exploratory manner. The objective of this study is also to
      evaluate the safety, the dose-response and the urinary excretion of pharmacodynamic (PD)
      marker after 24-week repeated oral doses of TAS-205 in DMD patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">October 17, 2017</completion_date>
  <primary_completion_date type="Actual">May 15, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline to 24 weeks in the 6-minute walk distance (6MWD)</measure>
    <time_frame>baseline, 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to 12 weeks in the 6MWD</measure>
    <time_frame>baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in time to rise from the floor</measure>
    <time_frame>baseline, 12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in time to walk/run for 10meters</measure>
    <time_frame>baseline, 12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in time to up and go (TUG)</measure>
    <time_frame>baseline, 12 and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline to 24 weeks in skeletal muscle mass using muscle CT</measure>
    <time_frame>baseline, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in lean body mass on bioelectrical impedance analysis (BIA)</measure>
    <time_frame>baseline, 1, 2, 4, 8, 12, 18, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in quantitative muscle strength using hand-held dynamometer (ex.microFET2)</measure>
    <time_frame>baseline, 12, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in serum Creatine kinase concentration</measure>
    <time_frame>baseline, 1, 12, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in pulmonary function as measured by spirometry</measure>
    <time_frame>baseline, 1, 4, 12, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events and side effects</measure>
    <time_frame>up to 27 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The urinary excretion amount of PD marker (PGD2 metabolite) in 24 hr-pooled urine</measure>
    <time_frame>baseline, 0.5, 12, 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>TAS-205（Low dose group）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TAS-205（High dose group）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAS-205</intervention_name>
    <description>2 groups: Low dose group, High dose group. Oral administration for 24 weeks, bis in die (BID) after meal</description>
    <arm_group_label>TAS-205（Low dose group）</arm_group_label>
    <arm_group_label>TAS-205（High dose group）</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 group: Placebo group. Oral administration for 24 weeks, BID after meal</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to give an informed consent. If applicable, able to give an informed assent.

          -  Phenotypic evidence of DMD.

          -  Male and ≧5 years of age.

          -  Bodyweight ≧7.5 kg and ＜60 kg.

          -  Able to complete the 6MWD test with a distance of at least 75 m.

          -  Able to take tablets.

          -  If taking oral glucocorticoids no significant change in the total daily or dosing 6
             months before enrollment.

        Exclusion Criteria:

          -  Any serious drug allergy.

          -  A forced vital capacity (FVC) of &lt;50% of predicted value.

          -  Wearing a respirator continuously (except for the use during sleep).

          -  A left ventricular ejection fraction (EF) of &lt;40% or fractional shortening (FS) of
             &lt;25% on echocardiogram.

          -  Clinically significant cardiac failure and respiratory failure.

          -  Ongoing immunosuppressive therapy (other than corticosteroids) .

          -  Surgical history or plan for surgery that may affect muscular strength or motor
             function.

          -  Any injury that may affect muscular strength or motor function.

          -  With any systemic allergic disease or any chronic inflammatory disease.

          -  Previous gene therapy (exon skipping, or stop codon read through therapy), cell-based
             therapy, or any other investigational agents.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taiho Pharmaceutical Co., Ltd.</last_name>
    <role>Study Director</role>
    <affiliation>Taiho Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nagoya City University Hospital</name>
      <address>
        <city>Aichi</city>
        <zip>467-8601</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Nagara Medical Center</name>
      <address>
        <city>Gifu</city>
        <zip>502-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe University Hospital</name>
      <address>
        <city>Hyogo</city>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Utano Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>616-8255</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinshu University Hospital</name>
      <address>
        <city>Nagano</city>
        <zip>390-8621</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Niigata National Hospital</name>
      <address>
        <city>Niigata</city>
        <zip>945-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Toneyama National Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>560-8552</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Higashisaitama Hospital</name>
      <address>
        <city>Saitama</city>
        <zip>349-0196</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>162-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Center of Neurology and Psychiatry</name>
      <address>
        <city>Tokyo</city>
        <zip>187-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tottori University Hospital</name>
      <address>
        <city>Tottori</city>
        <zip>683-8504</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2016</study_first_submitted>
  <study_first_submitted_qc>April 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2016</study_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

